BOCA RATON, FL (BocaNewsNow.com) (Media Advisory) — The Christine E. Lynn Women’s Health & Wellness Institute at Boca Raton Regional Hospital is the first in Florida to offer SenoClaireTM three- dimensional breast tomosynthesis by GE Healthcare. The versatile imaging technology provides mammograms with higher resolution, lower radiation and better detection for patients with all types of breast tissues, resulting in a safer and more confident screening.
While other programs moved quickly to introduce first-generation technology, the Hospital waited until it could provide its patients safer tomosynthesis. SenoClaireTM is the only 3D breast tomosynthesis approved by the U.S. Food and Drug Administration that delivers the same low dose as 2D screenings, with a 3D view dose at least 40 percent lower than other 3D mammography on the market.
SenoClaireTM is also the only USFDA-approved digital breast tomosynthesis to use a “step-and- shoot” method, a short X-ray sweep around the positioned breast, to acquire exposures. Since the tube comes to a complete stop when capturing each one of the nine exposures, this technique removes potential motion from the tube and helps reduce blur and increase image sharpness.
Moreover, 3D mammography can improve cancer detection in patients with dense breasts, according to a study released at the latest meeting of the Radiological Society of North America. Common among women, dense breasts have more fibrous or glandular tissue versus fatty tissue. Though cancer is more likely to develop in dense breasts, 2D mammography may not always
accurately detect it. The SenoClaireTM imaging technique, however, separates tissues and reduces overlapping of structures, enabling better characterization of malignant and benign findings.
“We are pleased to bring our patients the latest in 3D mammography, advancing our ability to provide women with a more personalized and precise screening process,” said Kathy Schilling, MD, Medical Director of the Lynn Women’s Health & Wellness Institute. “As we know, there is a better rate of survival when cancer is discovered and treated early. This technology marks another significant step forward in enhancing our clinicians’ ability to detect masses and small microcalcifications, which can represent cancer at its most curable stages.”